Ann: CHF Phase 3 Trial Results Presented at Investor Conference, page-2

Key Conclusions of the Presentation, .... wording,
looks like great presentation. ... there was much debate and analysis re the results yesterday,
the summary looks well presented but the wording and hence interputation is again different in clarity of what the 86% covered apposed the the 15th Dec, and/or relevance to that first read/out.
still all good, and assume this is part of then needed peer review process... we would like to see an expect FDA meeting timeline? not just expect to seek a meeting, and a supportive/positive novartis statement - to put pressure on the FDA.
Impatient i am yes. They have been to many delays, and FDA stuff up already not to impatient.